Abstract
Commentary to: A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49 Guozheng Liu, Shuping Dou, Stephen Baker, Ali Akalin, Dengfeng Cheng, Ling Chen, Mary Rusckowski and Donald Hnatowich